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Background: The use of fecal calprotectin (FCal) as a marker of intestinal inflammation, 
in the management of inflammatory bowel disease (IBD) is increasing. The aim of this 
study was to examine the impact of FCal measurements on decision-making and clinical 
care of children with IBD.
Materials and methods: In a retrospective cohort study, FCal, clinical activity indi-
ces, and blood markers were measured in children with established diagnoses of IBD. 
Pearson correlation coefficient analysis was performed to examine association between 
FCal and other markers. Decisions based on FCal measurements were prospectively 
documented and participants were evaluated 3–6 months later.
results: A total of 115 fecal samples were collected from 77 children with IBD 
[median age 14, interquartile range (IQR) 11–15.6 years, 42 females, 37 with Crohn’s 
disease]. FCal positively correlated with clinical activity indices (r =  0.481, P <  0.05) 
and erythrocyte sedimentation rate (r = 0.40, P < 0.05) and negatively correlated with 
hemoglobin (r = −0.40, P < 0.05). Sixty four out of 74 (86%) positive FCal measurements 
(≥250 μg/g of stools) resulted in treatment escalation with subsequent significant clinical 
improvement while in the FCal negative group, 34 out of 41 (83%) measurements 
resulted in no change in treatment and were associated with remission on follow-up.
conclusion: Based on high FCal, the majority of children had treatment escalation 
that resulted in clinical improvement. FCal measurements were useful and reliable in 
decision-making and clinical care of children with IBD.
Keywords: calprotectin, children, colitis, crohn, iBD
inTrODUcTiOn
Stool markers such as fecal calprotectin (FCal) have emerged as new diagnostic tools to help in 
the diagnosis of intestinal inflammation (1). Fecal inflammatory markers include a biologically 
heterogeneous group of substances that either leak from or are actively released by the inflamed 
mucosa. Calprotectin is a small calcium binding protein consisting of two heavy and one light 
Abbreviations: FCal, fecal calprotectin; IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis.
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polypeptide chains (a heterodimer of two S100 proteins) (1). 
It is found in neutrophilic granulocytes, accounting for 60% 
of their cytosolic fraction, and in monocytes and macrophages 
(1–3). It has a homogeneous distribution in feces. In active 
inflammatory bowel disease (IBD), an increased migration 
of inflammatory cells including neutrophils to the inflamed 
intestinal mucosa has been observed. Due to leukocyte shed-
ding in the intestinal lumen, pro-inflammatory proteins such as 
calprotectin can be detected and measured in the stools. FCal 
demonstrates good sensitivity and specificity as a marker for 
mucosal inflammation (1–4).
Inflammatory bowel disease is a chronic disease characterized 
by remissions and relapses and encompasses two related but 
distinct disorders of as yet unknown etiology: Crohn’s disease 
(CD) and ulcerative colitis (UC) (5). Both adult and pediatric 
investigators have recognized the need to optimize and standard-
ize methodology for assessment of disease activity. In children, 
active disease can have devastating consequences on growth and 
development. Consequently, it is prudent that disease remis-
sion is induced and maintained (6). The goal for IBD therapy is 
increasingly becoming mucosal healing. Therefore, the need for 
non-invasive, reliable, and relatively non-expensive biomarkers 
for IBD disease activity is growing (7).
Fecal calprotectin concentrations may correlate well with 
both endoscopic and histological IBD activity, which have been 
traditionally used to evaluate mucosal healing and response to 
treatment (8–10). However, the impacts of FCal measurement on 
decision-making and clinical outcomes in children with IBD are 
currently under-reported. The aim of this study was to examine 
the impact of FCal measurements on decision-making and clini-
cal care of children with IBD in usual clinical care.
MaTerials anD MeThODs
study Population
In a single centre cohort study, consecutive children with estab-
lished diagnoses of IBD assessed between November 2013 and 
December 2015 in the Pediatric IBD Outpatient Clinic at the 
Children’s Hospital, Winnipeg, MB, Canada, who had developed 
new symptoms that might had suggested a disease relapse were 
asked to bring in a stool sample for FCal measurement. Inclusion 
criteria included all children (<18 years) with confirmed diag-
nosis of IBD following the North America Society of Pediatric 
Gastroenterology, Hepatology and Nutrition diagnostic criteria 
for IBD (11).
covariate Data
Patients’ demographics and disease characteristics and dura-
tion were collected from patients’ medical records. The most 
significant symptom or sign as an indication for requesting FCal 
measurement was prospectively documented for each collected 
sample.
Fecal Calprotectin
Fecal samples were collected at home and processed at the labo-
ratory of the University of Manitoba IBD Clinical and Research 
Centre. FCal measurement was performed using the Quantum 
Blue® Lateral Flow Reader within 24  h of stool collection. 
FCal ≥ 250 μg/g of stools was considered a positive test, indicative 
of active IBD. The upper limit of test was >1,800 μg/g of stools.
Clinical Activity Indices
Clinical activity indices [pediatric UC activity index (PUCAI) 
for UC and pediatric Crohn’s activity index (PCDAI) for CD] 
(12, 13) and the impact of FCal testing on the management 
of IBD—investigations or changes in therapy—were assessed. 
Physician global assessment (PGA) for disease activity, 
whether it is quiescent, mild, moderate, or severe, was also 
documented (14).
Other Laboratory Markers
Included hemoglobin, erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), and serum albumin performed within 
2 weeks of stool collection for FCal.
When patients were asked to bring stool samples, pediatric 
gastroenterologists were asked to complete a questionnaire. 
Other investigations such as hemoglobin, serum albumin, and 
CRP were known to physicians who made no changes in treat-
ment at that time point. All patients with diarrhea had their stools 
tested for infection screen and only those with negative infection 
screen had stools for FCal measurements. The clinicians were 
asked to decide if they would do any additional investigations 
(mainly colonoscopy) or any changes in therapy, based only on 
the FCal results. Clinicians were given specific options to choose 
from for treatment escalation in case FCal comes back as posi-
tive. Once the FCal results were known, any investigations and 
treatment changes were documented and patients were followed 
up for 3–6 months. Clinical activity indices were measured in the 
follow-up visits.
If colonoscopy was performed following FCal results, colo-
noscopy findings and histopathology of collected mucosal biopsy 
samples performed within 1 month of collecting stool samples 
were examined. Presence of erythema, loss of vascularity, friabil-
ity, and/or ulcerations were included in the definition of active 
disease on endoscopy (active vs. inactive).
statistical analysis
Calculations and data analysis were performed using Statistical 
Package for the Social Sciences (SPSS, IBM Corp., 2013, IBM 
SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA). 
Descriptive measures [medians, interquartile range (IQR), means, 
ranges, and SD] were calculated for continuous variables (such as 
age and clinical disease activity indices), while frequencies were 
calculated for categorical variables (such as PGA), along with 
95% confidence intervals (CIs) for the means and proportions. 
Variables were examined for normal distribution. Student’s t-test 
was used to compare means. Categorical variable comparisons 
were performed using Fisher’s exact test. Pearson correlation 
coefficient analysis was performed to examine any possible asso-
ciation between FCal values and clinical disease activity indices, 
ESR, CRP, serum albumin, hemoglobin (all continuous vari-
ables), PGA (as a categorical variable; quiescent, mild, moderate, 
and severe), and endoscopic activity (as a dichotomous variable; 
active vs. inactive). A P value < 0.05 was considered significant.
TaBle 3 | indications (most significant symptom/sample) for fecal calpro-
tectin measurements in 77 children with inflammatory bowel disease.
Abdominal pain 38
Bleeding per rectum 24
Diarrhea 22
Weight loss 15
Fatigue 8
Others (e.g., constipation, abnormal labs) 8
Total 115
TaBle 2 | Base line medications of all participants.
Medication numbera
5-ASA 55
Azathioprine 38
Methotrexate 11
Infliximab 31
Adalimumab 9
Enteral nutrition 3
Steroids 11
Antibiotics 1
aSeveral patients were on more than one medication.
TaBle 1 | Demographic characteristics and disease phenotype in 
participants.
Number 77
gender
Male 35
Female 42
Diagnosis
Ulcerative colitis (UC) 37
Crohn’s disease (CD) 38
IBD-U 2
age
Median 14
Mean 13.08
Range 3.16–17.25
Uc phenotype
E1 3
E2 5
E3 16
E4 15
cD phenotype
location
Small bowel 7
Colon 8
SB-Colon 23
Upper GIa 19
Perianal 12
Behavior
Inflammatory 29
Stricturing 7
Fistulizing 2
aUpper GI involvement in combination with other phenotypes.
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ethical considerations
The study protocol was approved by the University of Manitoba 
Health Research Ethics Committee. As the study was retrospec-
tive, individual consents from participants were not needed.
resUlTs
Over the study period, a total of 115 fecal samples were collected 
from 77 children with IBD (median age at FCal measurements 
14, IQR 11–15.6  years, 42 females, 37 with CD), who were 
followed up for a median duration of 1.33 (IQR 0.5–3.1) years 
(mean 2.62 ± 1.84 years). Participants’ demographics and disease 
distribution are summarized in Table  1. Base line medications 
were summarized in Table 2.
The most significant symptom or sign such as diarrhea, weight 
loss, and pallor as an indication for FCal measurement is listed 
in Table 3.
Seventy four (64%) stool samples were positive (≥250 μg/g) 
and 12 participants had colonoscopy within 4  weeks of FCal 
measurement as compared with two patients in the group with 
normal FCal measurements (P < 0.001).
association between Fcal and study 
co-Variables
For the whole cohort, 74 (66%) out of 115 fecal samples had high 
FCal >  250 μg/g of stools. In 33 (44.6%) out 74 positive fecal 
samples, clinical activity indices were ≥10. On the other hand, 
41 (34%) out 115 fecal samples had normal FCal level and only 
2 (5%) out of 41 samples had clinical activity indices ≥10. Both 
patients were scoped and colonoscopy was normal.
Fecal calprotectin measurements had fair correlation with 
clinical disease activity indices (r  =  0.483, P  <  0.05), PGA 
(r = 0.40, P < 0.05), ESR (r = 0.40, P < 0.05), low hemoglobin 
(r = −0.40, P < 0.05), with less correlation with low serum albu-
min (r = −0.3, P < 0.05) but no correlation with CRP (r = 0.1, 
P = 0.3).
When those with CD were compared to the UC/IBD-U group, 
the correlation of FCal with clinical disease activity indices was 
stronger for UC compared to CD. High FCal levels correlated 
with PUCAI (r = 0.80, P < 0.01) compared to PCDAI (r = 0.2, 
P = 0.09).
Correlation was limited (r = 0.256, P = 0.006) with endoscopic 
activity as only 14 children had colonoscopy within 4 weeks of 
FCal measurement.
impact on Management
Only 14 (12%) out of 115 samples resulted in colonoscopy as 
guided by physicians’ discretion (likely when physicians felt 
that FCal value was equivocal between 100 and 250); 2 in FCal 
negative and 12 in the FCal positive group, i.e., for the rest of 
the cohort [101 (88%) samples], decisions on treatment (escala-
tion or no treatment) were based solely on FCal measurements. 
Sixty four out of 74 (86%) samples with positive FCal measure-
ments were associated with treatment escalation that resulted 
in improvements in clinical activity indices (Table 4), while in 
the FCal negative group, 34 out of 41 (83%) measurements were 
associated with no change in treatment.
Figure 1 summarizes the impact of FCal measurements on the 
study cohort over time. In the first follow-up visit 3–6 months 
following changes in treatment in the FCal positive group, of 
those measurements that resulted in treatment escalation, 80% 
TaBle 4 | changes in treatment based on 74 fecal samples with abnormally high fecal calprotectin.
change in medications change in  
medications (%)
Mean disease activity 
index before the change
Mean disease activity  
index after the change
P value, 95%  
confidence interval
Starting/switching a biologic 18 (24.3%) 20 ± 15.86 5 ± 2.04 P < 0.05, 6.81–14.43
Increase the dose/reduce time interval 
of a biologic
15 (20.3%) 16.6 ± 9.14 12.03 ± 8.37 N.S, −2.28 to 12.28
Increase dose of the immunomodulator 15 (20.3%) 13.8 ± 7.61 8.63 ± 6.3 N.S, −0.67 to 13.4
Adding an immunomodulator 5 (6.6%) 23 ± 8.3 6.25 ± 4.33 P < 0.05, 3.25–26.71
Adding steroids 7 (9.4%) 17.14 ± 9.49 13.12 ± 9.43 N.S, −18.14 to 11.84
Increase/add 5-ASA 7 (9.4%) 15.63 ± 10.48 7.5 ± 6.123 N.S, −6.17 to 22.44
No change of treatment 10 (2 declined change) (13.5%) 10.83 ± 6.05 5.7 ± 4.3 N.S, −5.8 to 18.4
Total 67a 12.83 ± 12.68 5.25 ± 7.15 P < 0.05, 4.48–11.34
aSixty-four changes in treatment (three samples resulted in more than one change in medication).
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ultimately achieved clinical remission while in the FCal negative 
group, 32 out 34 (94%) of those who did not have any treatment 
changes (including 2 patients with clinical activity indices >10), 
were in clinical remission at the follow-up visit.
DiscUssiOn
Fecal calprotectin is a surrogate marker for mucosal inflam-
mation and has been proven as a very beneficial, non-invasive, 
and relatively an inexpensive test in the work-up of IBD with a 
considerable high sensitivity (15, 16). Although high FCal can be 
found in other gastrointestinal disorders, in addition to IBD, such 
as gastrointestinal infections and polyposis, proper use of this test 
may reduce the need for frequent colonoscopies (15).
Our study showed a fair positive correlation of high FCal with 
increased clinical disease activity, a finding that is concordant 
with other adult and pediatric studies (9, 17–19). It is noteworthy 
that 55% of persons with increased FCal were in clinical remis-
sion by a symptom based activity index. While this may lead 
some to consider that this suggests that either the FCal is non-
specific, or that a substantial proportion of children with IBD 
in remission have active inflammatory disease. The majority of 
our subjects with elevated FCal had treatment escalation (even 
if disease activity index suggested remission). In pediatric IBD 
practice, our study is unique in that we relied on FCal to direct 
clinical management and then followed up to determine if our 
FCal-directed management led to satisfactory clinical outcomes 
several months later.
Bunn et  al. examined FCal in spot fecal samples from 37 
children with IBD and 31 control children. FCal was higher in 
16 children with UC and in 21 children with CD (18). Similar to 
our study, FCal concentration correlated negatively with serum 
albumin concentration (18). In another study from Italy, FCal 
showed a high correlation with the histologic grade of mucosal 
inflammation, similar to that observed for endoscopy in 58 
children with IBD (19).
In our study, FCal, did not correlate that well with CRP, a 
finding which was also highlighted in other studies (20, 21). 
Schoepfer and colleagues concluded that FCal correlated better 
with endoscopic scoring than that with CRP (20, 21). Correlations 
with CRP, however, were r = 0.53 and 0.55 in 140 ileocolonic CD 
and 228 UC adult participants, respectively (18, 19). In our study, 
the assessment of association between high FCal and endoscopic 
disease activity was limited by the small number of patients who 
had colonoscopy and the non-validated categorical classification 
of endoscopic activity into two subcategories (active and inactive 
disease).
Our study showed a better correlation of FCal with PUCAI 
compared to PCDAI. FCal has been previously also found to be a 
stronger marker for UC compared to CD (22).
Monitoring disease activity in patients with IBD is crucial 
as mucosal healing has become now a new target for treatment. 
It has been established that calprotectin concentrations cor-
relate well with endoscopic and histological IBD activity (8, 9). 
However, data on the impact of FCal directing management in an 
IBD population, especially in children, are sparce. In our study, 
86% of positive samples resulted in escalation of treatment with 
subsequent improvement in the majority of participants and 
88% of negative samples resulted in no change of treatment and 
sustained clinical remission in the majority of participants in 
subsequent follow-up.
In a recent study from The Netherlands, clinical activity 
indices, FCal, and CRP were measured in 62 teenagers with IBD 
(31 with CD and 31 with UC), who were asked to evaluate their 
disease control (100% was the best disease control) and their dis-
ease control, according to participants’ opinion, was above 90% 
in two successive outpatient clinic visits. Unlike CRP, positive 
FCal was predictive of a clinical relapse in the subsequent visit 
in 60% of participants (23). In another prospective multicentre 
cohort study, stool samples from 101 children who were admitted 
with severe UC were obtained for measuring four different stool 
markers for inflammation including FCal. Repeat samples at 
discharge were obtained from 24 children. Although all markers 
were initially significantly elevated, FCal did not correlate that 
well with PUCAI which performed better than the fecal mark-
ers in predicting outcome following a course of intravenous 
corticosteroids. However, perhaps it was too soon to expect a 
significant drop in FCal following the short course of intravenous 
corticosteroids (24).
Eccles et al. collected data on the impact that FCal testing from 
119 clinic participants including 29 with IBD. FCal testing helped 
in assessment of disease activity and decision-making in 25 
adults with known IBD; 21 had major changes in their treatment 
while 4 were felt to be in remission on biological therapy (25). 
FigUre 1 | Flow chart summarizing the impact of fecal calprotectin measurements on the decision-making process among children with 
inflammatory bowel disease.
5
El-Matary et al. Calprotectin in Pediatric IBD
Frontiers in Pediatrics | www.frontiersin.org January 2017 | Volume 5 | Article 7
In four pediatric participants with known IBD, one had a normal 
FCal level and was felt to be in remission but three had elevated 
levels that resulted in major changes in management. Similar to 
our study, the investigators concluded that FCal can serve as a 
marker for disease activity in known IBD and help in the clinical 
decision-making process (25).
In an open label randomized controlled study, Osterman et al. 
observed significantly dropping FCal levels in adults with quies-
cent UC after escalating their mesalamine dose (26). In another 
randomized study, Lasson et  al. used FCal measurements to 
identify persons with UC who were at risk of relapse and escalated 
their therapy (27). Both studies, however, were experimental and 
not reflective of routine real-life clinical practice.
The limitations of our study include the retrospective design 
and small sample size especially for those who had colonos-
copy. However, based on previous research, FCal is known to 
strongly correlate with endoscopic disease activity (9, 17) and we 
assumed that it did. Hence, the escalation of treatment in most 
participants with elevated FCal levels regardless of whether a 
colonoscopy was performed or not. The study main aim was how 
FCal measurements, as the major decisive factor, would impact 
on disease management. A positive FCal most often triggered a 
clinical response; especially a change in therapy. As we did not 
do colonoscopy in all subjects we cannot discern how many 
false negative FCal measurements were represented within our 
sample. Nonetheless, our results did show that the faith clini-
cians placed in the FCal result was rewarded with good clinical 
outcomes. Another limitation was a lack of measurements of FCal 
in the follow-up visits after implementing changes in therapy but 
the study outcome was intended to be clinical activity indices. 
Nonetheless, the study adds significantly to the current literature 
as little is known about the impact and outcome of FCal measure-
ments in pediatric IBD clinical practice.
cOnclUsiOn
In children with known IBD, elevated levels of FCal were more 
likely to be associated with elevated scores of clinical activity 
indices, high ESR, and low hemoglobin. However, many children 
with elevated FCal had normal clinical disease activity indices. 
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Regardless of disease activity index at the time of FCal, based on 
abnormal measurements of FCal, the majority of children had 
their treatment escalated which resulted in significant clinical 
improvement in those with elevated disease activity index or sus-
tained remission in those in whom the index was considered in 
remission. On the other hand, the majority of those with normal 
FCal did not have any changes in their investigations or treatment 
and remained in clinical remission which saved patients and 
health-care resources from unnecessary interventions.
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